Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Interleukin 36 Receptor (IL36R) is a member of the interleukin-1 receptor family and forms a heterodimeric receptor complex with IL-1RAcP. Activation by its agonists (IL-36α, IL-36β, IL-36γ) triggers pro-inflammatory signaling pathways, while antagonists (IL-36Ra, Interleukin-38) block receptor activation. IL36R is predominantly expressed in epithelial tissues and plays a key role in innate and adaptive immunity. Dysregulation of IL36R signaling is implicated in various inflammatory diseases, making it a therapeutic target for conditions such as psoriasis and inflammatory bowel disease.
Agonist binding induces heterodimerization with IL-1RAcP, activating downstream NF-kB and MAPK signaling pathways. Antagonists block IL-1RAcP recruitment, preventing signal transduction.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin 36 Receptor (IL36R).